Brief: Ryvu Therapeutics Says That BioNTech Terminated STING Program
January 30 (Reuters) - Ryvu Therapeutics SA RVU.WA :
* SAID ON WEDNESDAY THAT BIONTECH HAS TERMINATED "STING"
PROGRAM
AND TWO OTHER PROGRAMS
* AFTER TERMINATION RYVU THERAPEUTICS TO REGAIN FULL RIGHTS
TO THE
PROGRAM
* BIONTECH TO FINANCE ALL R&D COSTS IN ONGOING COLLABORATION
WITH
RYVU
Source text: urn:newsml:reuters.com:*:nEM4wdVJda
Further company coverage: RVU.WA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Ryvu Therapeutics SA
See all newsBrief: Ryvu Therapeutics Q1 Net Loss 12.6 Million Zlotys
Brief: Ryvu Therapeutics Updates Romacyclib Development Strategy
Brief: Ryvu Therapeutics FY Net Loss At 101.2 Mln Zlotys
Brief: Ryvu Therapeutics Extends Research Collaboration And Exclusive License Agreement With BioNTech Until Nov 29, 2028
Brief: Ryvu Therapeutics Signs Grant Agreement With Poland's NCBR For PERO Project